Probiotic Sepsis Risk Low in Preterm Infants

Probiotic administration to very preterm infants is associated with a low risk of invasive infections, according to findings from a large retrospective cohort study published in JAMA Pediatrics. The research analyzed data from over 100,000 very preterm infants, identifying only 11 cases of invasive infections linked to Bifidobacterium or Lactobacillus probiotics. This suggests that the benefits of probiotics in this vulnerable population likely outweigh the minimal risks of infection.

The study, which examined infants born between 2000 and 2019 across 13 neonatal intensive care units (NICUs) in the United States, aimed to provide reassurance regarding the safety of probiotic use. Very preterm infants, defined as those born before 32 weeks of gestation, are particularly susceptible to infections due to their immature immune systems. Probiotics are often administered to these infants to promote gut health, potentially reducing the incidence of necrotizing enterocolitis (NEC) and sepsis, common and serious complications in this population.

Of the 11 identified invasive infections, the majority were bloodstream infections, with a smaller number being meningitis. The specific probiotic strains implicated were Bifidobacterium breve and Lactobacillus rhamnosus GG, two commonly used strains in neonatal care. The study's authors emphasized that while these infections are serious, their occurrence rate is exceedingly low when considered against the vast number of preterm infants who receive probiotics without adverse events. The retrospective nature of the study means it cannot establish causality but highlights a significant association and provides valuable real-world data on safety profiles.

Previous research and clinical practice guidelines have generally supported the use of specific probiotic formulations in very preterm infants, citing evidence of reduced NEC and improved outcomes. However, concerns about potential fungemia and bacteremia have persisted, prompting ongoing surveillance and research. This study's findings contribute to a growing body of evidence that, when appropriate strains and dosages are used under careful medical supervision, the risk of invasive probiotic-related infections remains exceptionally low. The study's large sample size and multi-center design lend considerable weight to its conclusions, offering a robust reassurance to clinicians and parents alike regarding the safety of this therapeutic intervention for extremely vulnerable newborns.